About Us | The iQ Group Global

AT THE iQ GROUP GLOBAL,

That’s all we think about

We are a consortium of companies who work together to find, fund and develop bioscience discoveries into life-changing medical innovations – and take them to the people who need them most.

Our scientific team identifies scientific discoveries from laboratories all over the world that have the potential to have life-changing impact.

Our corporate advisory and investment banking teams work together to translate scientific milestones into value creation events, creating financial instruments and corporate structures that activate commercial value.

Our commercialization team partners with healthcare providers and unlocks regulatory pathways to take the discovery to the people who need it.

The story so far

2020

OncoTEX team publishes landmark OxaliTEX preclinical trial findings in Proceedings of the National Academy of Sciences (PNAS).
iQNovate Ltd (NSX:IQN) name change to The iQ Group Global Ltd (NSX:IQG)

2019

The iQ Group Global acquires TEX Core, an oncology drug platform
Recognised as one of Australia and New Zealand’s Top 5 Most Innovative Companies by The Australian Financial Review and BOSS Magazine
FarmaForce wins Sales Team of the Year at PRIME Awards for the third time
Capital Labs raises more than $828,000 for healthcare startup

2018

China patent granted for Saliva Glucose Biosensor
FarmaForce wins Sales Team of the Year at PRIME Awards for the second time

2017

US patent granted for Saliva Glucose Biosensor

2016

The iQ Group Global accelerated the development of the Saliva Glucose Biosensor
iQ Capital incorporated in the USA
Series 8 Fund launched
FarmaForce wins Sales Team of the Year at PRIME Awards